@article{E Domingo-Domenech_E Gonzalez-Barca_C Estany_A Sureda_J Besalduch_A Fernandez de Sevilla_2002, place={Pavia, Italy}, title={Combined treatment with anti-CD20 (rituximab) and CHOP in relapsed advanced-stage follicular lymphomas}, volume={87}, url={https://haematologica.org/article/view/2560}, DOI={10.3324/%x}, abstractNote={We studied the safety and efficacy of combined treatment with rituximab plus CHOP in 16 patients with relapsed advanced-stage follicular lymphomas. The intent-to-treat overall response rate (ORR) was 88%, 75% complete remissions (CR) and 13% partial remissions (PR). At a median follow-up of 18 months, 63% of the patients are alive (50% CR). The combination of rituximab and CHOP in relapsed advanced-stage follicular lymphomas achieves high ORRs and CRs, with low toxicity except for in previously autografted patients.}, number={11}, journal={Haematologica}, author={E Domingo-Domenech and E Gonzalez-Barca and C Estany and A Sureda and J Besalduch and A Fernandez de Sevilla}, year={2002}, month={Nov.}, pages={1229-1230} }